Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Just confirming I'm not blowing smoke up my Yazhoo. On a Seeking Alpha article of a couple of days ago, I posted poziotinib is a $500M drug just based on EGFR Exon 20 Insertion in NSCLC using a back of the envelope calculation of 5000 pts (at last Q, they mentioned from 4000 to 7000 patients) * $100000 which equals $500M. Well, analysts are speculating that neratinib will come in at 126,000/yr.

PriceRx, an independent source of drug pricing information, provided the estimated wholesale acquisition cost of $10,500 a month for Nerlynx, or $126,000 a year—40% higher than he had previously predicted.

There are still some lingering concerns, however, about whether oncologists will use the new drug in as many patients at the FDA’s label allows. In one study, the drug seemed to provide only a modest overall benefit: 94.2% of patients taking it did not suffer recurrence or death after two years, vs. 91.9% of patients on a placebo. And because the biggest benefits were seen in hormone-receptor positive patients, some analysts are predicting oncologists will only use the drug in that population.

And let's not forget the severe diarrhea that goes along w neratinib. If poziotinib is successful in EGFR Exon 20 Insertion in NSCLC. it will be a treatment where PFS is only 1.9 months. If poziotinib is successful, and we'll get strong indications if that is so later this year i.e if P2 mirrors pre-clinical and compassionate patient results. Just wondering what poziotinib should cost.

http://www.fiercepharma.com/financials/puma-s-breast-cancer-drug-nerlynx-to-command-10k-a-month-despite-concerns-report?utm_medium=nl&utm_source=internal&mrkid=899996&mkt_tok=eyJpIjoiTUdVeU16ZGxabUpsT0RjeCIsInQiOiJWeUd3eXFVeXBBKzJNZCtIeG1qRXVTRHdRNnVxM2hqRUo4QjE0V1grcG1cL2U2ZEl5MHpEenU0eTRydGVvclwvbnpZXC9ESFwvSU9oRnB1bXMxU1JPanRBK1U4em5LWDdub1JtWFwvNnRzUnVVemN6Z05ESm9TaXNPTVh2NDhSMERwbmJIIn0%3D